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CoV2‑ID, a MIQE‑compliant 
sub‑20‑min 5‑plex RT‑PCR 
assay targeting SARS‑CoV‑2 
for the diagnosis of COVID‑19
Stephen Bustin1*, Amy Coward2, Garry Sadler2, Louise Teare2 & Tania Nolan1
Accurate, reliable and rapid detection of SARS‑CoV‑2 is essential not only for correct diagnosis of 
individual COVID‑19 disease but also for the development of a rational strategy aimed at lifting 
confinement restrictions and preparing for possible recurrent waves of viral infections. We have used 
the MIQE guidelines to develop two versions of a unique five plex RT‑qPCR test, termed CoV2‑ID, 
that allows the detection of three viral target genes, a human internal control for confirming the 
presence of human cells in a sample and a control artificial RNA for quality assessment and potential 
quantification. Viral targets can be detected either individually with separate fluorophores or jointly 
using the same fluorophore, thus increasing the test’s reliability and sensitivity. It is robust, can 
consistently detect two copies of viral RNA, with a limit of detection of a single copy and can be 
completed in around 15 min. It was 100% sensitive and 100% specific when tested on 23 RNA samples 
extracted from COVID‑19 positive patients and five COVID‑19 negative patients. We also propose 
using multiple cycle fluorescence detection, rather than real‑time PCR to reduce significantly the 
time taken to complete the assay as well as assuage the misunderstandings underlying the use of 
quantification cycles (Cq). Finally, we have designed an assay for the detection of the D614G mutation 
and show that all of the samples isolated in the Chelmsford, Essex area between mid‑April and June 
2020, have the mutant genotype whereas a sample originating in Australia was infected with the wild 
type genotype.
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 as the causal agent 
of the COVID-19  disease1,2, and the ongoing pandemic has highlighted many of the inadequacies inherent in 
current diagnostic testing  regimens3. As a result, the development of nucleic acid-based tests using different 
molecular approaches has been rapid. SARS-CoV-2 is currently identified using real-time reverse transcription 
(RT)-qPCR4, isothermal  methodologies5,6 or  CRISPR7,8. Isothermal approaches typically require more develop-
ment and optimisation but have the advantage of speed and are more readily implemented into point-of-care 
 systems9. PCR based assays have the advantage of simplicity of design, easier multiplexing potential and in most 
cases, greater sensitivity. Typical commercial tests use a one tube combined RT and amplification protocol, are 
carried out in fairly large volumes and use slow protocols with real time data acquisition that result in typical 
assay times of 1–1.5 h. They are broadly comparable, although their reported sensitivity of 500 viral copies per 
 reaction10 is significantly lower than generally achievable using this technology, and assays differ significantly 
in the speed of their overall  workflow9. Although a more recent publication describes a streamlined assay with a 
detection limit of 15 copies, this is based on experiments performed by spiking total human RNA with in vitro 
synthesised viral transcripts, and the total workflow time remains at 2 h11. Most SARS-CoV-2 RT-qPCR assays 
target two viral genes, and positive results are most commonly obtained through the hydrolysis of dual-labelled 
 probes12. Targeting more than one viral gene is advisable as there are reports of significant false negative rates 
for SARS-CoV-2 RT-qPCR  testing13,14. A potential challenge for any nucleic-acid based testing methods is the 
potential of the virus to mutate and an analysis of primer binding sites targeted by RT-qPCR assays has indeed 
shown that a high percentage are  mutated15. A mutation in a reverse primer has been shown to affect the sensi-
tivity of an RT-qPCR assay in use early in the  pandemic10 and further mutations could lead to the occurrence of 
false negative results, particularly if the mutation occurs at the extreme 3′ end of the primers. Since false negative 
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results could also be due to sampling difficulties, poor recovery of RNA, the presence of PCR inhibitors or human 
error, it is essential that the RT-qPCR assay itself is the least likely cause and includes controls to reveal as many 
areas of assay vulnerability as possible.
The principal aim of current SARS-CoV-2 diagnostic tests is to detect unambiguously the presence or absence 
of viral targets. Where viral load is not being determined, there is no requirement to quantify viral load and 
therefore no need to detect amplification products in real-time16. Instead, we have developed a multiple cycle 
fluorescence detection protocol that measures baseline fluorescence towards the beginning of the run and then 
records discrete increases after a specified number of cycles to detect target-dependent amplification, whilst at 
the same time saving the considerable time it takes to scan a plate at the end of each cycle.
Consequently, we set out to design an RT-qPCR test that can be used qualitatively or quantitatively, in addi-
tion to being sensitive, specific and fast. The Minimum Information for Publication of Quantitative Real-Time 
PCR Experiments (MIQE)  guidelines17 were used as the basis for establishment of the workflow, resulting in 
CoV2-ID, a SARS-CoV-2-specific five plex RT-PCR test (Fig. 1).
This assay ensures specificity by targeting multiple SARS-CoV-2 genes (Nsp10, Nsp12 and N) in line with the 
WHO guidelines for the reliability of results, which require at least two genomic targets for diagnostic  tests18, with 
neither primers and probes amplifying or detecting any other coronaviruses. The assay also includes a human 
control target (JUN) to confirm the presence of human cells and an extraction and inhibition control artificial 
sequence (EICAS) that can be used to monitor the performance of the assay and detect sample-induced reaction 
 inhibition19. We have used droplet (dd) PCR to delineate quantification and detection limits of this assay, which 
can detect a single viral genomic target. Furthermore, having previously demonstrated that PCR reaction times 
can be significantly reduced by using shorter denaturation and polymerisation times and altering the denatura-
tion and polymerisation  temperatures20, we have developed a high-speed qPCR protocol that can be completed 
in around 15 min, depending on the instrument used. In addition, we demonstrate the feasibility of using a 
multiple cycle fluorescence detection protocol to reduce assay times even further.
Figure 1.  MIQE-compliant workflow used to characterise, optimise and validate the components that make up 
CoV2-ID assay.
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Materials and methods
The details of all reagents, plastic ware and instruments are listed in the supplementary data file, Table 1.
Ethics statement. All methods were carried out in accordance with relevant guidelines and regulations. 
This study and experimental protocols were approved by the Research Ethics panel of the University’s Faculty 
for Health, Education, Medicine and Social Care, reference HEMS-FREP 19/20/039. Analyses were performed 
on existing and anonymised RNA samples collected during standard diagnostic tests, with no clinical or epide-
miological data available, apart from each reported quantification cycle (Cq). Consent was not required as the 
UK Human Tissue Authority has indicated that stored samples that have been taken for diagnosis and remain 
after the diagnostic procedure has been completed can be used in approved research, providing that all samples 
are anonymised to researchers.
Sample collection, RNA extraction, selection and storage. Nasopharyngeal/nose and throat/throat 
samples were collected for routine SARS-CoV-2 testing by trained staff at Mid and South Essex NHS Foundation 
Trust Broomfield using a variety of swab types. RNA was extracted within 24 h of sample collection and eluted in 
a final volume of 50 µL RNase-free water. The standard protocol was modified to include an incubation at room 
temperature for 10 min in a Class 1 safety cabinet, before incubating at 56 °C for 10 min.
All RNA samples were stored at − 80 °C. Further validation of RNA sample quality was not possible due to 
diagnostic requirements, however subsequent testing with the EICAS assay (detailed below) provided a measure 
of inhibitory  contamination19.
A total of 23 clinical RNA samples, in four batches (labelled A through D), testing positive for SARS-CoV-2 
and one set of five samples testing negative at Broomfield Hospital were selected at random from those remaining 
after routine clinical tests. 5 µL aliquots were transported on ice for 3 miles from the hospital pathology laboratory 
to the Molecular Biology research laboratory (Anglia Ruskin University, UK). One of these samples had very 
high concentrations of viral RNA (A4) and so was diluted 1:100 with sterile RNase-free water and used for assay 
development. Eight further samples (A1 and C1-C7) were diluted 1:30 and used for optimisation, validation and 
comparative analyses. All samples were stored at − 80 °C until further use. Two control samples were included 
for development of the genotyping assay (kindly donated by J. Curry, LGC, UK). This first was RNA isolated 
from cell culture infected with Sars-CoV-2 which was isolated from a clinical sample at Westmead Hospital 
(New South Wales, Australia); COVID19 was confirmed using N1/N2 and E gene RT-qPCR) and the second, a 
synthetic control RNA (Twist Biosciences), which were included as wild type controls for D614G genotyping.
Primers and probes. Human SARS-CoV-2 (NC_045512.2) and SARS-CoV-1 (NC_004718.3) reference 
sequences and a Bat SARS-like coronavirus genome (MG772933) were downloaded to the Allele ID 7 qPCR 
assay design software package and SARS-CoV-2 specific primers and probes were designed with manual adjust-
ments aimed at maximising the analytical sensitivity and robustness of the assay. Three SARS-CoV-2 targets, 
Nsp10, N-gene and Nsp12, were chosen to accommodate sequence variabilities in primer or probe locations and 
minimise the likelihood of a 3′-mutation at primer binding sites reducing the reliability of the assay. JUN was 
chosen as a human extraction control to verify that human nucleic acid was present in the sample; it is intron-
less, thus permitting detection of DNA and RNA, has low tissue-specificity and is highly expressed in proximal 
digestive tract (https ://www.prote inatl as.org/ENSG0 00001 77606 -JUN/tissu e). The specificity of primers, probes 
and amplicons was analysed in silico using Primer-BLAST (https ://www.ncbi.nlm.nih.gov/tools /prime r-blast /) 
and BLAST (https ://blast .ncbi.nlm.nih.gov/Blast .cgi).
In addition, the human SARS-CoV-2 (NC_045512.2) genomic sequence was imported to the Beacon Designer 
8.2 qPCR assay design software package and an LNA-based genotyping assay for discriminating the D614G 
mutation (A to G) was designed. Finally, two extraction and inhibition control artificial sequences (EICAS1 
and 2) were designed so that they contained no matching sequences in published databases. EICAS1 is ampli-
fied using a bespoke primer set, whereas EICAS 2 was designed with terminal 5′ and 3′ sequences amplified by 
the JUN primers, to avoid potential primer interference during the multiplex PCR. EICAS1 and EICAS2 are 
detected by the same probe.
Upon receipt, all DNA oligonucleotides were resuspended in sterile RNase-free water at 100 µM and stored 
in aliquots at − 20 °C. The RNA oligonucleotides were diluted to 1 × 10–9 relative to the original stock with sterile 
RNase-free water and stored at − 80 °C.
RT, qPCR and digital PCR. RNA extracted from clinical samples at a dedicated COVID-19 testing facil-
ity at the Broomfield Hospital Microbiology laboratory was tested for SARS-CoV-2 using Viasure’s single tube 
RT-qPCR protocol. RNA (5 µL neat sample) was tested in a final reaction volume of 20 µL, with a 15 min/45 °C 
RT step, 2-min polymerase activation step and 45 cycles of 10 s/95 °C denaturation and 50 s/60 °C annealing 
and polymerisation step using Biomolecular Systems’ Mic qPCR cyclers with manual threshold setting. Clini-
cal laboratory testing protocols regarded samples as positive for SARS-CoV-2 if a Cq < 38 was recorded either 
for both ORF1ab and N gene targets or ORF1ab alone. The newly designed SARS-CoV-2 test described in this 
report, termed CoV2-ID, was validated on the 23 clinical samples (batches A–D) samples using a modified sin-
gle tube RT-qPCR protocol (PrimeScript III, Takara and 1Step Go, PCRBio) with 1 µL RNA in a final reaction 
volume of 5 µL, a 5 min/50 °C RT step, 1 min polymerase activation and 40 cycles of 1 s/95 °C denaturation and 
1 s/60 °C annealing and polymerisation. Absence of contamination was determined by running no template 
(NTC) and no RT (NRC) controls.
Subsequent one-step combined RT and qPCR reactions were carried out with 0.5 µL RNA, of sample-depend-
ent, varying and unknown concentration, per 5 µL reaction. Where two tube reactions were carried out, 1 µL 
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RNA was reverse transcribed in 10 µL with Superscript IV Vilo using random primers; EICAS cDNA synthesis 
was supplemented with specific reverse primer (R) at 10 nM final concentration. RT conditions were 5 min at 
25 °C, 5 min at 50 °C and 5 min at 95 °C and cDNA was diluted into 20 µL of water, with 1–5 µL used for further 
analysis.
Primer optimisation was carried out using PrimeScript III by comparing Cqs using combinations of forward 
and reverse primers at 0.3, 0.6 and 1 µM and choosing the concentrations that recorded the lowest Cq. Probe 
optimisation was carried out by comparing Cqs obtained using 0.4 µM or 0.8 µM final probe concentration. 
Optimal annealing temperatures were determined by using SARS-CoV-2 cDNA and the temperature gradient 
option available on the BioRad CFX followed by melt curve analysis, together with SensiFast SYBR Green mix 
and optimal primer concentrations. Ideal annealing temperatures were identified as those resulting in the lowest 
Cq whilst retaining a single melt curve peak.
Minimum qPCR run times were established by preparing a single master mix, sufficient to carry out all 
experiments. The master mix consisted of SensiFast qPCR Probe mix, SARS-CoV-2 cDNA, and primers and 
probes specific for the targets and was kept on ice until required. 5 µL aliquots were subjected to qPCR for 
decreasing denaturation and polymerisation times, with 1 s for each step being the minimum possible on the 
qPCR instruments used.
The experiments aimed at reducing RT times were initially carried out as using PCRBio One Step RT-qPCR 
reagent, as the RT is supplied separately from the buffer. A 1× master mix of SARS-CoV-2 sample and EICAS 
RNA, CoV2-ID assay oligo blend (targeting Nsp10, N-gene, JUN and EICAS2) and RT-qPCR buffer was prepared 
and kept on ice. Immediately prior to each run, 10 µL of that master mix was placed in a microfuge tube, 1 µL 
of PCRBio RT was added and 2 × 5 µL were added to two wells of a 48 well qPCR plate. The plate was briefly 
spun and subjected to different RT times, with qPCR times kept constant. All experiments were repeated using 
PrimeScript III, but since this reagent is a single tube mixture of buffer and RT, a premix of RNAs, CoV2-ID and 
water was prepared, and 2× PrimeScript III mix was added just prior to each run.
RT-qPCR reactions were carried out on the following instruments: CFX (BioRad), Eco (PCRBio), Prime Pro 
(Techne) or Mic (BMS). Data were analysed using instrument software, Microsoft Excel for Mac v.16.38 and 
PRISM for Mac v.9.
Droplet digital PCR (ddPCR) reactions were set up as instructed in the operating guide using the QX200 
droplet generator (BioRad), clear well semi-skirted 96 well plates, pierceable foil and PX1 PCR plate sealer 
(BioRad). Each reaction contained concentrations of cDNA corresponding to the ones used in parallel qPCR 
experiments, with the optimal primer and probe concentrations established for qPCR runs, which are slightly 
different from the recommended ones for primers (0.9 µM) and probe (0.25 µM). Following droplet generation, 
PCR reactions were carried out in 40 µL volumes on a C1000 Touch Thermal cycler (BioRad) using the standard 
program of 10 min enzyme activation at 95 °C, and 40 cycles of 30 s denaturation at 94 °C and 1 min annealing/
polymerisation at 60 °C, with the ramp rate set to 2 °C/s. The droplets were analysed immediately on the QX200 
reader. RT-ddPCR reactions added a 1 h reverse transcription at 45 °C at the start of the PCR protocol. Data 
were analysed using QuantaSoft Analysis Pro and QX Manager software.
Multiple cycle fluorescence detection PCR. Multiple cycle fluorescence detection PCR assays were 
carried out using SensiFast in 5 µL volumes using the protocol shown in Table 1 on the CFX Connect instru-
ment (BioRad). The first plate read after cycle 8 was used to establish a baseline fluorescence, thus allowing the 
calculation of fluorescence increases after cycles 15, 20, 25, 30 and 35. In each case the relative fluorescence 
change (∆F) was calculated by subtracting the cycle 8 fluorescence reading from the fluorescence readings after 
the respective cycles.
Results
Assay design and characteristics. In silico analysis by PrimerBlast and BLAST analyses of primers, 
probes and amplicons signified that all virus oligonucleotide sequences were specific for SARS-CoV-2 and that 
the assays were not complementary to any other coronavirus. Since the oligonucleotide manufacturer enclosed 
a cautionary note with primer and probe shipments indicating that they “could contain trace amounts of long 
oligo templates” specifying SARS-CoV-2 sequences, all panels were immediately assessed in qPCR assays with-
out addition of template. None resulted in amplification signals, demonstrating that they were not contaminated 
with either SARS-CoV-2 or JUN templates. Assay details, oligonucleotide sequences, fluorophores, final opti-
mised annealing temperatures (Ta) conditions and PCR efficiencies are shown in Table 2.
The supplementary data file contains the detailed optimisation results for primer and probe concentrations 
(Table 2) and Tas (Table 3). All six assays resulted in efficient RT-qPCR assays, ranging from 94 to 103% (Table 2) 
with melt curves resulting in a single peak, indicating the amplification of a single amplicon (Supplementary 
Figure S1).
A conservative limit of quantification was established based on results from ddPCR experiments using Nsp10. 
Results from a five-fold serial dilution series indicated that quantification was linear down to around 50 copies 
(Supplementary Figure S2a,b). In order to determine whether this was the approximate threshold of reliable 
and reproducible quantification, seven individual dilutions of the template were subjected to ddPCR assay. The 
results establish that this assay can reliably quantify 41 ± 12 copies of viral target (Supplementary Figure S2c,d), 
although this limit is lower if additional probes are used (see below). In order to translate this to an RT-qPCR 
limit of detection (LOD) for viral targets, the sample containing 50 copies was diluted further to nominal 10, 
5, 2 and 1 copies and subjected to qPCR amplification using the Nsp10 assay. This resulted in the detection of 5 
copies by 12/12 replicates and two and one copies by 10/12 and 8/12 replicates, respectively (Fig. 2a), with similar 
results obtained with Nsp12 (Fig. 2b). A repeat experiment using the dilution that had a predicted two-copy per 
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reaction detected Nsp10 presence in 24/24 reactions (Fig. 2c). Underlying data are presented in supplementary 
data Table 4.
Comparison of assay performance; individual or multiplex assays. To reduce sample processing 
time, reduce reagent usage and increase throughput it was desirable to optimise the assays to run in multiplex. 
Two viral targets (Nsp10 (FAM) and N-gene (Texas Red), JUN (Cy-5) and EICAS2 (HEX) panels were combined 
to form the initial assay. Cq values obtained from assays run individually were compared with those obtained 
in the multiplex reaction. The assays perform equally well in both conditions (Fig. 3, supplementary data file 
Table 5) with only JUN amplification being approximately two cycles later in the multiplex reaction. This was 
solved by increasing the JUN primer concentration to 1.3 µM (Supplementary data file Table 5a).
The performance of the two EICAS assays and their effect on the amplification of the other markers was 
compared by carrying out four replicate multiplex RT-qPCR with either EICAS1 or EICAS2 as the internal 
control. Results were similar, suggesting that the inclusion of the additional primer set required for EICAS1 had 
no detectable adverse effect on assay performance (Supplementary data file Table 6).
Assay validation. For validation of this test panel, 1 µL RNA was used per sample to reanalyse all 28 clini-
cal samples and our results were 100% concordant (Table 3; Cqs are shown in supplementary data file Table 7).
For sample A8, Broomfield Hospital recorded discordant ORF1ab/N-gene results but these were positive for 
both markers when tested with our panel. Six positive and four negative samples were also tested using a com-
mercial diagnostic kit (Sansure), with comparable results. In this case, the commercial kit did not detect one of 
the viral targets (ORF1ab) in sample B1, which was detected both at Bromfield Hospital and with our panel. There 
was significant correlation between Cqs recorded for Nsp10 and N-gene (r (95%CI) = 0.96 (0.89–0.98) as well 
as between Nsp 10 or N-gene and JUN (r = 0.73 (0.45–0.88) and 0.86 (0.68–0.94, respectively (Supplementary 
Figure S3 and supplementary data file, Table 7). An analysis of all clinical samples using the D614G genotyping 
assay revealed that all isolates harboured the A to G transition, characteristic of the more infectious phenotype, 
whereas the control clinical sample and Twist BioScience control 1 were both wild type, A, at this location (sup-
plementary data file, Table 7).
Inclusion of the EICAS template in the assay panel permitted some analysis of the quality of RNA extracted 
from patient samples. If inhibitors of the RT or the PCR were present in the clinical samples, an increase in 
Cq was expected for the EICAS assay compared with no template control samples, analogous to the principle 
underlying the SPUD  assay19. An analysis of the 28 samples revealed little, if any inhibition, with a median Cq 
Table 1.  Protocol for multiple cycle fluorescence detection.
Step Reaction Temperature (ºC) Time (s) Number of cycles
Activation 95 30 –
Amplification 1
Denaturation 93 1
7
Polymerisation 64 1
Detection cycle 8
Denaturation 93 1
1
Polymerisation 64 1
Amplification 2
Denaturation 93 1
6
Polymerisation 64 1
Detection 15
Denaturation 93 1
1
Polymerisation 64 1
Amplification 3
Denaturation 93 1
4
Polymerisation 64 1
Detection cycle 20
Denaturation 93 1
1
Polymerisation 64 1
Amplification 4
Denaturation 93 1
4
Polymerisation 64 1
Detection cycle 25
Denaturation 93 1
1
Polymerisation 64 1
Amplification 5
Denaturation 93 1
4
Polymerisation 64 1
Detection cycle 30
Denaturation 93 1
1
Polymerisation 64 1
Amplification 6
Denaturation 93 1
4
Polymerisation 64 1
Detection cycle 35
Denaturation 93 1
1
Polymerisation 64 1
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of 27.07 (range 25.57–29.12) compared with the median Cq of 27.08 (range 27.54–26.91) recorded by no control 
samples (Supplementary data file, Table 7a).
The C to T transition at the − 9 position in the Nsp10 F primer binding site of isolate MT412262 did not 
impede the binding of the CoV2-ID F primer to mutant target (Supplementary Figure S4a). The reverse was 
also true, in that the mutant primer bound efficiently to the WT target (Supplementary Figure S4b). In each case 
the qPCR data were in broad agreement with the ddPCR results. Targets with mutations at positions − 10 and 
− 7 at the N-gene primer binding site were also efficiently amplified by the CoV2-ID F primer (Supplementary 
Figure S5c), as was the WT sequence by the two mutant primers (Supplementary Figure S5d). Since a mutation 
had been identified for three isolates (MT506889/506904/506907) at position 2 of the 5′-end of the N-gene probe, 
the effect of that mutation on the efficiency of amplicon detection by the N-gene probe was also investigated. 
Two specific probes were synthesised, one with (MuN) and one without (N-Pr2) the mutation at position 2 of 
the probe. Both gave virtually the same results (Supplementary Figure S5a), as did an alternative probe with 
WT sequences (Supplementary Figure S5b). The performance of both CoV2-ID and mutant primers with their 
respective templates was further analysed using an annealing temperature gradient analysis, which showed that 
the mutations had little effect on assay performance below 65 °C. Details of all underlying data for both qPCR 
and ddPCR results are listed in the supplementary data file Tabs 8, 8a, 8b and 8c.
Table 2.  Details of oligonucleotide sequences, fluorophores, optimal concentrations and annealing 
temperatures used for the detection of SARS-CoV-2 targeting Nsp10, N-gene, Nsp12, JUN and EICAS, 
collectively referred to as CoV2-ID. All oligonucleotides are listed in the 5′-3′ direction. Nucleotides that 
differ from the SARS-CoV-2 reference sequence, but have been detected at low frequency are shown in red. 
Oligonucleotides are based on the following accession numbers: Reference SARS-CoV-2: NC_045512; mutant 
SARS-CoV-2: MT412262 (F-primer 10Mu); MT607612/481905/496997/467255/467251 (F-primers NA and 
NB); MT506889/506904/506907 (Probe MuN); c-JUN: NM_002228.4.
Target Target Amplicon (bp) Oligonucleotides (5′-3′) Final conc. (µM) Ta (°C)
SARS-CoV-2
Nsp10 85
F: GGA TCA AGA ATC CTT TGG TGG 1
64.0R: GTC ACA AAA TCC TTT AGG ATT TGG A 1
Pr: FAM-CAT CGT GTT GTC TGT ACT GCC GTT 
GCC-Q 0.4
N-gene 88
F: GCT GCT AGA CAG ATT GAA C 1
60.5
R: AGC AGA TTT CTT AGT GAC AGT TTG 1
Pr1:-TR-ATG TCT GGT AAA GGC CAA CAA CAA 
CA-Q 0.4
Pr2: TR/FAM-TCT GGT AAA GGC CAA CAA CAA 
CAA GG-Q 0.4
Nsp12 96
F: CAT CCC TAC TAT AAC TCA AAT GAA 1
62.0R: GTC ATA GTA CTA CAG ATA GAG ACA C 1
Pr: FAM-TGC AAA GAA TAG AGC TCG CAC CGT -Q 0.4
Mu-Nsp10 85 (10Mu) GGA TCA AGA ATC TTTT GGT GG 1 61.0
Mu-N-gene 88
(NA) GCT GCT TGA CAG TTTG AAC 1 62.0
(NB) GCT GCT TGA TAGA TTG AAC 1 60.3
MuN: TR-TTTGG TAA AGG CCA ACA ACA ACA 
AGG -Q 0.4
D614G mutation 104
F: CAC CAG GAA CAA ATA CTT C 1
R: CCA AGT AGG AGT AAG TTG A 1
WT: FAM-ctttAtcAggAtgTtaact-Q 0.4
Mu: HEX-ctttAtcAggGtgTtaact-Q 0.4
mRNA control JUN 88
F: CGC CTG ATA ATC CAG TCC A 1
60.5R: GCT CAT CTG TCA CGT TCT TG 1
Pr:- Cy5-CAC ATC ACC ACC ACG CCG ACC-Q 0.4
EICAS1
– 58 F: AAC AAC CAC ACC AAAAC 
R: GGA GGT TTT AGT TTGG 
Pr: HEX-CAC ACA ACA CCA ACA AAA CCA AAC 
A-Q
rArArCrArArCrCrArCrArCrCrArArArArCrCrArCrArCrArArCrArCrCrArArCrArArArArCrCrArArArCrArCrCrA-
rArArCrUrArArArArCrCrUrCrC
EICAS2
– 65 Pr: HEX-CAC ACA ACA CCA ACA AAA CCA AAC A-Q
rCrGrCrCrUrGrArUrArArUrCrCrArGrUrCrCrArUrCrArCrArCrArArCrArCrCrArArCrArArArArCrCrArArA-
rCrArCrArArGrArArCrGrUrGrArCrArGrArUrGrArGrC
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Conversion to a five plex assay and simplification. ddPCR data suggested that targeting two viral 
targets (Nsp10 and 12) using the same flurophore (FAM) increased the sensitivity of the assay by around 80% 
(Supplementary Figure S6a,b) and that there could be some benefit in a qPCR setting, especially with regards to 
further reducing the likelihood of a false negative result (Supplementary Figure S6c,d with well statistics and Cqs 
listed in supplementary data file Table 9).
To test this concept, Nsp12 was added as a third viral target to the four plex CoV2-ID assay, making it a five 
plex, with two of the viral targets being detected on the FAM channel. The results confirmed a reduction in Cq 
in the FAM channel, without affecting any of the other results (Supplementary Figure S7, with underlying data 
in supplementary data file Table 10). Performance of the four- and five plex assays was further assessed in four 
additional patient samples and the results indicated that they performed comparably, with the viral targets being 
detected earlier in the five plex assay (Supplementary Figure S8, with underlying data in supplementary data 
file Table 11). Finally, in order to determine whether the sensitivity of the assay could be increased further, the 
five plex assay was modified so that all three viral targets (Nsp10, Nsp12 and N-gene) were detected with FAM-
labelled probes. Both qPCR (Figure S9a,b) and ddPCR (Supplementary Figure S9c,d) data revealed that there 
was indeed a further increase in sensitivity (data in supplementary data file Table 12).
Development of rapid cycling conditions. In order to further improve the potential throughput of 
the assay in a diagnostic setting, the ability of the assay to perform adequately under short RT times and fast 
PCR conditions was tested. Baseline Cq data from the initial conditions of 10 min RT, 5 s denaturation and 10 s 
polymerisation were obtained for all three viral targets. Then RT time was reduced to 5 min, followed by step-
wise reduction of both denaturation and polymerisation times to 1 s each, although in practice, the annealing/
polymerisation step took around 6 s, as the fluorescence scanning required around five seconds. There was no 
decline in the performance of the assay, but the run times were reduced from 33 min 40 s to 20 min (Fig. 4a, with 
data in supplementary data file Table 13). The initial 5 s/10 s and final 1 s/1 s conditions were applied to replicate 
five plex assays, and the results confirmed that all panels could be run using this protocol (Fig. 4b; with data in 
supplementary data file Table 13b).
The next aim was to try and reduce run times by further reducing the RT times. The results shown in sup-
plementary Figure S10 (underlying Cqs are in supplementary data file, Table 14) suggested that a 1-min RT step 
resulted in Cqs similar to the 5-min RT reaction, reducing run times to 16 min.
Reductions in run times could also be achieved on instruments not designed to run as fast as the PCRMax/
Techne, as shown for the BioRad CFX. Here the reduction in RT time from 10 to 1 min and cycling times from 
95 °C/5 s and 60 °C/20 s, to 1 min RT and 1 s each at 95 °C and 60 °C reduced the run time from 58 to 32 min. 
The Cqs from seven targets present at a wide range of concentrations were compared and there was very little 
difference. Indeed, most of the targets recorded slightly lower Cqs with the fast run (supplementary data file, 
Table 14a).
Since the cooling step is the slowest part of the PCR cycle in block-based qPCR instruments, reducing the 
temperature gap between denaturation and annealing/polymerisation temperatures should further reduce run 
times. Following an initial calibration run with a 1 min RT step followed by 1 s 95 °C denaturation and 60 °C 
annealing/polymerisation steps, denaturation temperatures were reduced and annealing/polymerisation tem-
peratures were increased. Even without further modifications to primer or enzyme concentrations, the small 
differences in Cq (Fig. 5, with Cqs in supplementary data file, Table 15) indicated that this would be a potential 
method to reduce reaction times further, in this case from 16 to 14 min 11 s.
Multiple cycle fluorescence detection. We have developed a multiple cycle fluorescence detection 
(MCFD) protocol linked to a 5-level rating algorithm. This resulted in faster run times and permitted the inclu-
sion of the quantitative information inherent in qPCR without the confusion surrounding the use of quantifica-
Figure 2.  LOD for Nsp10 and 12. (a) Individual Cqs from 12 replicates of patient-derived samples containing 
nominal SARS-CoV-2 copies of 10, 5, 2 and 1 (determined by ddPCR), detected using the Nsp10 assay. (b) Cqs 
from 10 replicates with 5 or 1 copy of target obtained for Nsp12. (c) Cqs from repeat reaction of 10 replicates 
with 5 or 1 copy of target obtained for Nsp10.
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Table 3.  Validation of 28 RNAs extracted from patients attending Broomfield Hospital between April and 
June 2020. The four positive (A-D) and single negative batches were collected at different times. Negative test 
results are highlighted in bold. The Viasure data were obtained at the hospital, and ten of the samples were 
screened using a commercial kit (Sansure). The result of the genotyping tests are also shown.
Sample Date
Viasure COV2-ID Sansure
ORF1ab N IC Nsp10 N JUN EICAS ORF1ab N IC D614G status
A1 24-04-2020  +ve  +ve  +ve  +ve  +ve  +ve  +ve – - - Mutant (G)
A2 29-04-2020  +ve  +ve  +ve  +ve  +ve  +ve  +ve – - - Mutant (G)
A3 30-04-2020  +ve  +ve  +ve  +ve  +ve  +ve  +ve – - - Mutant (G)
A4 01-05-2020  +ve  +ve  +ve  +ve  +ve  +ve  +ve  +ve  +ve  +ve Mutant (G)
A5 01-05-2020  +ve  +ve  +ve  +ve  +ve  +ve  +ve – - - Mutant (G)
A6 03-05-2020  +ve  +ve  +ve  +ve  +ve  +ve  +ve – - - Mutant (G)
A7 03-05-2020  +ve  +ve  +ve  +ve  +ve  +ve  +ve – - - Mutant (G)
A8 03-05-2020 −ve  +ve  +ve  +ve  +ve  +ve  +ve – - - Mutant (G)
B1 14-04-2020  +ve  +ve  +ve  +ve  +ve  +ve  +ve −ve  +ve  +ve Mutant (G)
B2 26-04-2020  +ve  +ve  +ve  +ve  +ve  +ve  +ve  +ve  +ve  +ve Mutant (G)
B3 26-04-2020  +ve  +ve  +ve  +ve  +ve  +ve  +ve  +ve  +ve  +ve Mutant (G)
B4 26-04-2020  +ve  +ve  +ve  +ve  +ve  +ve  +ve  +ve  +ve  +ve Mutant (G)
B5 27-04-2020  +ve  +ve  +ve  +ve  +ve  +ve  +ve  +ve  +ve  +ve Mutant (G)
C1 14-04-2020  +ve  +ve  +ve  +ve  +ve  +ve  +ve – - - Mutant (G)
C2 15-04-2020  +ve  +ve  +ve  +ve  +ve  +ve  +ve – - - Mutant (G)
C3 15-04-2020  +ve  +ve  +ve  +ve  +ve  +ve  +ve – - - Mutant (G)
C4 15-04-2020  +ve  +ve  +ve  +ve  +ve  +ve  +ve – - - Mutant (G)
C5 17-04-2020  +ve  +ve  +ve  +ve  +ve  +ve  +ve – - - Mutant (G)
C6 17-04-2020  +ve  +ve  +ve  +ve  +ve  +ve  +ve – - - Mutant (G)
C7 19-04-2020  +ve  +ve  +ve  +ve  +ve  +ve  +ve – - - Mutant (G)
D1 13-06-2020  +ve  +ve  +ve  +ve  +ve  +ve  +ve – - - Mutant (G)
D2 27-04-2020  +ve  +ve  +ve  +ve  +ve  +ve  +ve – - - Mutant (G)
D3 13-06-2020  +ve  +ve  +ve  +ve  +ve  +ve  +ve – - - Mutant (G)
E1 N/A −ve −ve  +ve −ve −ve  +ve  +ve −ve −ve  +ve N/A
E2 N/A −ve −ve  +ve −ve −ve  +ve  +ve −ve −ve  +ve N/A
E3 N/A −ve −ve  +ve −ve −ve  +ve  +ve – - - N/A
E4 N/A −ve −ve  +ve −ve −ve  +ve  +ve −ve −ve  +ve N/A
E5 N/A −ve −ve  +ve −ve −ve  +ve  +ve −ve −ve  +ve N/A
n = 28
Figure 3.  Comparison of Cqs obtained from single- and multiplex assays for the four panels making up 
CoV2-ID. The line through the box shows median Cqs and the whiskers denote minimum and maximum Cqs.
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tion cycles. The feasibility of using this method rather than real-time detection was tested by comparing the per-
formance of the two approaches using the same master mixes. As the PCRMax/Techne software does not permit 
a PCR run to be carried out without collecting fluorescence data, the experiment was carried out on the BioRad 
CFX. Whereas the standard qPCR run took 43 min to complete, the MCFD run took just over 22 min. The 
results for five different concentrations of viral target, together with the NTC control are shown in Fig. 6a, with 
the proposed algorithm in Fig. 6b. All underlying MCFD data are shown in supplementary data file Table 16.
Quantification potential. The inclusion of ddPCR quantified, internal EICAS, facilitates an indirect 
measurement of copy number, thus allows this RNA to function both as a measure of quality control, as well as 
an assessment of viral load.
The same quantity of Nsp10 target was detected using qPCR as well as digital PCR. The results shown in 
Supplementary Figure S11a demonstrate how the reported Cq depends on the threshold setting, which is sub-
jectively set by the operator or automatically determined by a software algorithm that can vary between runs 
and instruments. This interferes with accurate quantitative reporting of SARS-CoV-2 viral loads, as the highest 
and lowest threshold-dependent Cq recorded in that run varies by 8.7, ie corresponds to a 400-fold difference. 
In contrast, the copy numbers calculated using the ddPCR platform showed little variation, recording an average 
Figure 4.  Reduction in qPCR times. (a) Cqs obtained for Nsp10, 12 and N-gene by reduction of qPCR times 
from 5 s denaturation and 10 s annealing polymerisation to 1 s each. (b) Comparison of the initial (5 s/10 s) and 
final (1 s/1 s) denaturation/annealing and polymerisation qPCR protocols. The assays were run in duplicate, 
with the plots showing the ∆Cqs between the longer and shorter timings.
Figure 5.  Reduction in denaturation and polymerisation times. The ∆Cqs for each of the five targets are plotted 
for each of the different temperatures used to carry out the PCR reactions.
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copy number of 1163 ± 61 (Supplementary Figure S11b) Underlying data are shown in supplementary data file 
Table 17.
Discussion
The COVID-19 pandemic, caused by the new SARS-CoV-2 virus, has led to the development of a wide range of 
diagnostic assays, many of which are RT-PCR based, utilise real time detection and report a Cq value to indicate 
presence or absence of the virus. However, it has become increasingly clear that there are significant shortcom-
ings in the use and interpretation of many of these assays for testing and monitoring populations for viral spread. 
This has resulted in some confusion as to whether these diagnostic assays are capable of adequately addressing 
their three main functions: First, to identify patients presenting with symptoms consistent with COVID19 as 
SARS-CoV-2 positive or negative. Second, to provide a meaningful assessment of viral load, given that Cqs are 
subjective and not sufficiently reproducible or robust to allow an appraisal of the validity of marginal results, i.e. 
those around cycle 35. Third, to monitor the spread of virus using screening programmes of populations and 
environmental samples, allowing that a high percentage of those infected remain asymptomatic.
In general, the most critical features of a diagnostic assay are high specificity and sensitivity, with reliability, 
speed, and ease of use also being highly desirable. In addition, where large numbers of samples are processed, 
cost saving on reagents is a serious consideration. Well-designed RT-qPCR assays certainly fulfil the first two 
criteria and have the potential to meet the remaining ones. Each of the three scenarios above requires a subtle 
variation on assay design and application. In the first case, the assay must be highly specific, reliable, sensitive 
and rapid. At this stage a binary positive or negative readout is sufficient. However, in the second scenario where 
therapy may be informed by an indication of viral load, the assay requires the same features with the addition 
of a quantitative assessment. Finally, widespread screening protocols benefit from low cost, high throughput 
and require simple binary readout without the absolute requirement to reduce time. The assay described in this 
communication, termed CoV2-ID, has been developed to be adapted to any of the situations described.
CoV-2-ID offers maximum sensitivity by targeting three viral targets and detecting their presence using the 
same fluorophore, building on a previous report, which used two hydrolysis probes to increase the sensitivity 
Figure 6.  Multiple cycle fluorescence detection PCR results. (a) Four replicates were assayed for five samples 
containing different concentrations of Nsp12 amplicons, together with a NTC. Fluorescence data were collected 
at cycles 8, 15, 20, 25, 30 and 35 and for each replicate the fluorescence recorded at cycle 5 was subtracted from 
the fluorescence recorded at each subsequent fluorescence collection cycle. The difference in fluorescence was 
plotted for each cycle, with the horizontal bar indicating the median fluorescence. The run took just over 22 min 
to complete. (b) Algorithm incorporating the fluorescence data into a diagnostic assessment tool, obviating the 
need to deal with Cqs and cut-offs.
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of a SARS-CoV-2  assay21. This is appropriate for a diagnostic test, which does not need to distinguish between 
different viral targets and increases the sensitivity by around threefold, thus improving on currently used com-
mercial assays.
Whilst it may be desirable to measure viral load in patients exhibiting COVID-19, there is considerable 
misunderstanding with regards to the quantitative interpretation of diagnostic RT-qPCR test results. These 
are routinely recorded as stark Cqs, which can be rather misleading. When RT-qPCR is used to quantify gene 
expression, Cqs are normalised against reference genes, with amplification efficiencies determined by dilution 
 curves22 and meaningful quantification dependent on efficiencies being similar between targets of interest and 
reference genes. Importantly, if not normalised, Cq values are subject to inherent inter-run  variation23 and are 
operator, reagent- and instrument-dependent. Huge variations in Cq value ranges of up to 21 Cqs, the equiva-
lent of a 2 × 106-fold difference, have been reported for the same clinical virology run controls run in different 
 laboratories24. Consequently, results are not readily comparable when carried out using different master mixes, 
instruments and analysis criteria and should not be used without appropriate calibration  standards17. Since Cq 
values are affected by numerous parameters, not least by operator intervention with regards to threshold set-
tings, as shown in Supplementary Figure S11, they must not be used quantitatively and should not be used to 
determine viral loads. Hence, in the absence of certified controls or even validated standards, the inclusion of 
the EICAS RNA control template, quantified by ddPCR, allows not just monitoring of the RT-qPCR reaction but 
also quantification of viral load. It must be stressed, however, that any quantitative data will still be laboratory-
specific, and that use of the EICAS must be validated separately and repeatedly in different laboratories. The 
EICAS serves additional control functions in the assay: It provides an indication of potential inhibitors of the RT 
or PCR within the sample and has the potential to serve as an RNA extraction control. The addition of an intron 
less human gene control permits screening of samples for nucleic acid content regardless of whether DNase is 
used during sample preparation.
The single tube reaction format, with low volumes and all reagents premixed, results in a simple workflow 
and we have minimised RT and qPCR  times20 to generate an assay that can be run in less than 20 min on a suit-
able instrument. Furthermore, since it is useful to run a diagnostic test as quickly as possible, we have combined 
endpoint and real-time analysis by measuring fluorescence towards the beginning of the run and then monitoring 
any increase at defined intervals thereafter. This permits the detection of target-dependent amplification, whilst 
at the same time saving the considerable time it takes to scan a plate at the end of each cycle. Our data demon-
strate that this results in fast run times, even on an instrument such as the BioRad CFX, which is not optimised 
for maximum speed. The incorporation of defined fluorescence detection cycles into a reporting algorithm also 
has the advantage of allowing the quantitative aspect of qPCR to be used to generate a viral load determination, 
without resorting to the use of a subjective Cq or controversial cut-off point. This algorithm associates increases 
in fluorescence with a 5-level ratings system that can be used to inform further action, with any patient test-
ing at level 1 being retested immediately. Importantly, this protocol can be applied to most conventional qPCR 
instruments, in contrast to a recent report that requires specialist  instrumentation25.
It is widely accepted that SARS-CoV-2 mutations are arising constantly, although there is still no evidence for 
the evolution of distinct phenotypes in SARS-CoV-226. Nonetheless, a SARS-CoV-2 variant carrying the Spike 
protein amino acid change D614G has replaced the original D614A variant in many  locations27–29. This muta-
tion increases  infectivity30,31 and may increase the severity in infected  individuals32, although it remains unclear 
what the impact of the mutation on transmission, disease, and vaccine and therapeutic development  is33. These 
data certainly support the finding that this variant is ubiquitous, as all of the UK isolates tested back as early as 
14th April carry the D614G mutation.
Although human coronaviruses harbour a proofreading exoribonuclease, a number of location-specific muta-
tions have been identified in the genome of SARS-CoV-2 that result in potential mismatches with all published 
primer and probe sequences (https ://covid 19.edgeb ioinf ormat ics.org/#/assay Valid ation )15. Hence, it is important 
to continue monitoring any assay, so as to sustain routine scrutiny of sequence mutations in primer and, to a 
lesser degree, probe binding regions of the viral genome, as recommended by the American Society for Micro-
biology COVID-19 International  Summit34. CoV2-ID targets three viral genes, as this allows scope for the test 
to remain accurate even if mutations arise at the 3′-ends of the primers that could result in false-negative results. 
Our analysis of the effects of mutations in primers suggest that their impact is limited, as long as they are not at 
the 3′-ends of the primers. Variants with C to T transitions at positions − 9 and − 10 and an A to T transversion 
at position − 7 of the N-gene present a frequency of 0.006%35 displayed no difference in sensitivity compared to 
the WT assay. Two mutations within the N-gene probe binding site, one a G to T transversion at 5′-end nucleo-
tide 3, the other a C to T transition at nucleotide 5 with respective frequencies of 0.053% and 0.029% also had 
no discernible effect on sensitivity.
CoV2-ID is presented as an adaptable assay that can be applied to all SARS-CoV-2 detection and quantifica-
tion applications. In presenting the development of this assay we also sought to provide maximum transparency 
for the verification process, effect of protocol variations and the requirement for adequate standards and con-
trols in order for the assay to be reliable and robust. The current pandemic has revealed shortcomings in global 
response procedures and it is essential that public health institutes, regulatory bodies and standards organisations 
adopt a shared set of guidelines, protocols and standards that allow a common and meaningful interpretation 
of any emerging molecular testing regimen.
In conclusion, we have used the MIQE guidelines to design, develop, optimise and validate CoV2-ID, an 
enhanced, value-added RT-qPCR assay specific for SARS-CoV-2. It is robust, sensitive and is optimised for a rapid 
protocol, providing the opportunity for high throughput, multiplex viral detection with the potential to quantify 
viral load. Its design minimises the likelihood of assay failure causing false negative test results and its robust-
ness provides a promise for its further development as an extreme PCR assay for use with point of care devices.
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